Latest News

We focus on local and international deals up to US$500 million in value across a wide range of sectors. Since the start of 2012 our partner firms have collectively completed over 230 deals, in 30 countries worldwide with an aggregate value of over US$17.5 billion.

Going Public Magazine interviews Stefan Constantin of C.H Reynolds on Biotech

10th May 2011

When thinking about M&A transactions in white biotechnology, there are some particularities that need to be observed as they don’t occur in other industries including red biotech.

GoingPublic magazine interview with Stefan Constantin, Partner, C H Reynolds Corporate Finance AG. Download the attached PDF at the bottom of page for the original article. When thinking about M&A transactions in white biotechnology, there are some particularities that need to be observed as they don’t occur in other industries including red biotech. M&A consultant Stefan Constantin from C.H Reynolds explains what matters when making deals in industrial biotechnology. GoingPublic: Mr Constantin, you executed several deals in the white biotechnology field. What are the particularities compared to other industries? Constantin: Generally, we are talking about technology transactions more than sales or profitability driven transactions. Often, the size of the target company is only a small fraction of the size of the buyer. The turn - over range of most targets lies between single-digit and double-digit millions, whereas buyers are often medium-sized or multi-billion companies. Another particularity is that the span of the potential buyers universe is much wider than in other industries. GoingPublic: Does this refer to industries as well as to company sizes? Constantin: Yes, but it also shows the different positions in the value chain. The range of interested companies varies from big chemical and pharmaceutical players producing patented consumer end products, generics, detergents, food supplements or scent and flavor substances to active ingredient (API-)manufacturers or medium-sized or big suppliers of inter mediates. Real Biotech-Competitors show interest in acquisitions as well although only few of them are financially strong enough to acquire. Depending on the development stage of the target company, corporate VCs are amongst the interested parties, too. GoingPublic: Is the acquisition of technology the main driver, or do competitive aspects also play a role? Constantin: As part of the sales process you have to bear in mind different aims for each interested group. Companies like Pfizer, Boehringer or Henkel as well as big suppliers are interested in the savings within their own production process, e.g. replacing three chemical steps by one organic step. Competitors are more interested in complementarity or in different technologies. GoingPublic: What exactly are the differences between the red and white biotechnology in terms of trans actions? Constantin: There are huge differences in relation to the structures of transactions: The white biotech business model is often wider in potential applications and contains out-licensing and co-operations with big companies already. The business models in the red biotech area are more focused with every clinical phase, leaving diagnostics and other red biotechs aside. As a consequence, the range of potential exit buyers rather gets smaller than bigger as the company progresses. Additionally, red biotech companies are ultimately bought when their development phase is coming to an end. In the area of oncology for example, there are in certain situations only five or six global players that can be considered as potential buyers. GoingPublic: Do white biotech companies have to reach a certain stage of development in order to raise interest, or is technology itself the main driver? Constantin: In contrast to the red biotech industry where each clinical phase reached limits products, and helps for the next financing round, even young white biotech companies can raise an enormous amount of interest. What matters is whether they are able to prove the functionality of their products in large scale areas. We think that at least two or three anchor projects in the context of co-operations or out-licensing with industrial partners are necessary to get the sales process going. GoingPublic: Which role do VC and Private Equity play in the early stage of financing as well as on the vendor side? Constantin: VC investors play a dominant role in financing. At a certain time, they are looking for exit possibilities. They have to support the management in their clear strategy in order to gain sufficient return on investment. Therefore company structures with regard to IP and sales force have to be positioned in such a way that they can be introduced into the market. In other words: Organizational support and strategic investments are needed. VC alone cannot always deliver that. Due to the sizes of investments, Private Equity rather plays a supporting role as developments in white biotech are part of their equity stories for the bigger investments like Cognis, Evonik or Süd-Chemie, being hold or held by Permira, CVC or OEP. In white biotech, Private Equity is rarely seen as direct buyer. GoingPublic: Even though VC-financing plays a dominant role, isn’t there a need to catch up in comparison to the red biotechnology? Constantin: Yes, absolutely. Playing a dominant role in this case does not necessarily mean: on a high level. In Europe and the U.S., there is only a limited number of VC-financed white biotech companies. Their number is rising, also due to cost pressure within the pharma/ chemical industry and the suppliers. This is underpinned by the increase in co-operations. GoingPublic: In Germany, white biotech has not yet entered the stock exchange … Constantin:We think that there are four reasons for this: First, we are talking about extremely complex products or processes that can be introduced into several application areas. Furthermore, the business model requires technology to be up-scaled on an industrial level which needs further investment. Additionally, the question arises where the company will position itself in three or four years when it “should” also deal with sectors like the food industry. Can the company sufficiently grow without an exit to a strategic partner? Or will it be taken over and vanish from the stock markets? The equity story is important: Chances and risks are difficult to communicate to the market. GoingPublic: When listed on the stock market, the capital market could offer a reasonable financing alternative … Constantin: This is generally true, but to a certain extent, it depends on customers and products. B.R.A.I.N, an intelligently and broadly positioned company, is often considered as a stock market candidate. But sales teams for the different segments adhesives, pharmaceuticals etc. have to be financed – potentially also using Venture Capital. Again, the question arises: Where does the company want to stand in four years? A supplier for big players? There are other companies beyond the mark of EUR 300 million in sales able to either develop white biotech by themselves or to acquire it. GoingPublic: How important is the international aspect for transactions in white biotech? Constantin: An international capacity is crucial for selling white biotech companies. We felt that in all our processes. Some companies don’t pay attention to this size of potential targets, e.g. suppliers of the pharmaceutical industry with a turnover of 300 to 400 million Euros which themselves have been thinking about getting involved with biotechnology but didn’t make it. Addressing international companies on a strategic level is essential for success. GoingPublic: Not only across the borders, but also across continents? Constantin: Absolutely. Just look at Indian generics producers: They are observing the German market very carefully. GoingPublic: Mr Constantin, thank you very much for this informative interview. 109-67a80a2de604bc6e39d314af987088dd.pdf
Adobe Acrobat file - 0.4 mb

< Back

latest opinion

Impact of a strong Swiss franc on the M&A activity: challenges & opportunities

The discontinuation of the minimum CHF/EUR exchange rate triggered significant market reactions.…

Dissecting the Deal: Radiant Logistics, Wheels Group and the 3PL Size Premium

On January 20th, small-cap logistics provider Radiant Logistics, Inc. (NYSE MKT: RLGT) announced a deal to acquire Canadian 3PL Wheels Group, Inc. (TSXV: WGI) for approximately US$78 million…

Opting-out clause: does it still make sense in light of recent Sika transaction?

The sale of a controlling stake in Sika by long-term family shareholder to its French competitor Saint-Gobain has been widely discussed since its announcement last December.…

What to expect from the US in 2015

'Boring is better' is how one high profile investor in the US is describing the state of the world's largest economy.…

Life in the fast lane, the 2014 Fast Track 100

The latest Fast Track 100, The Sunday Times’ annual list of the fastest-growing privately-owned companies, shows that the UK’s SMI's are thriving…

Succession Planning as Part of the Wealth Management Strategy - Blair Roblin & Nathan Treitel

What All Wealth Managers Should Know About Their Client’s Family Business…

Significant growth in the global demand for sensors

Next years will see a significant growth in the global demand for sensors, with sales expected to increase by approx. 9% to reach €184m in 2016. The highest demand for sensors will be in the information and communications industry as well as in the automotive industry.…

The risk of a new tech bubble and how to respond as entrepreneur

A heat-up of valuations and transaction activity in the tech industry raises concerns that we have arrived in the next tech bubble.…

View more >

latest deals

Morrells - F T Morrells

Morrells is the UK’s largest manufacturer and distributor of high performance industrial wood finishes and application equipment. Typical applications for its products include kitchen, furniture…

R2B Inspecties - Safety

The CEO, owning the largest part of the shares was looking for continuity of the business after his planned retirement. Kiwa, an international well-known TIC…

ENERVENT (owner of a 37Mw wind energy plant) - WIND 2

NORGESTION has completed the sale of the 17% stake in ENERVENT owned by CATALUNYA CAIXA CAPITAL, the private equity subsidiary of CATALUNYA CAIXA, the Spanish…

Toridoll.Corporation - Project Ajax

Yamaichi and Capitalmind Corporate Finance Advisory jointly advised Toridoll.Corporation on the majority acquisition (60%) of restaurant chain Wok to Walk.

ARX

Established in 1993, the ARX group (the ‘Group’) of companies is Europe’s leading distributor of pharmacy automation solutions. The business specialises in providing automated storage…

Fini Nuair

The scope of the financing is to rebalance the capital structure and fund the acquisitions. In particular, the Group is pursuing two acquisitions, one in…

Finproject - Polyolefin

Ethica Corporate Finance advised Xenon private equity, minority shareholder of Finproject, – a leading Italian compounder and moulder of high-performance polyolefin – in the sale…

Cogipower - Solar

Ethica Corporate Finance advised the shareholders of Cogipower, a leading Italian renewable energy company owning ca. 57MWp of installed photovoltaic plants in Central and Southern…

Newport Diversified, Inc.

Headwaters MB advised Newport Diversified, Inc. and its affiliate, Broadacres Open Air Marketplace, LLC (collectively, the “Company”) on a senior debt refinancing led by California…

EPM Mining Ventures

Headwaters MB advised EPM Mining Ventures Inc. (“EPM”), a development stage mining company focused on specialty fertilizers, in closing an C$80 million combined pre-production and…

dotMed/Care2U - Project Care

Promedico took a strategic investment in dotMed/Care2U. Promedico is a software vendor in the primary healthcare sector, active as a supplier of information systems for…

PARQUE EÓLICO LOS PEDREROS (owner of a 50Mw wind energy plant) - WIND 3

NORGESTION has completed the sale of the 40% stake in PARQUE EOLICO LOS PEDREROS owned by CATALUNYA CAIXA CAPITAL, the private equity subsidiary of CATALUNYA…

Mespack

NORGESTION advised the shareholders of Mespack on its integration into the Illinnois based Duravant Group, global engineered equipment company with an over 100-year operating history,…

Peter Lang AG - Cordoba

The Peter Lang Chidren Trust based in the UK, decided to focus on their own field of expertise and to sell 100% of the shares…

K. R. Pfiffner AG - Picasso

The acquisition of Pfiffner further reinforces FFG’s position in Europe and provides complementary and leading expertise in high-volume and high-precision machining in the area of…

View more >